Y-mAbs Therapeutics (YMAB) Reports FDA Clearance of IND for Bispecific GD2 Antibody
December 10, 2018 5:40 PM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
